Trial site
Bekes Varmegyei Koezponti Korhaz
Bekescsaba, 5600, HungaryEU-13 widening countryNot linked to an institution yet
- 20running trials
- 16closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 216 trials
- Phase 2/33 trials
- Status
- Completed16 trials
- Recruiting12 trials
- Active, not recruiting7 trials
- Not yet recruiting1 trial
- Lead sponsor
- Merck Sharp & Dohme LLC4 trials
- Abivax S.A.3 trials
- Janssen Research & Development, LLC3 trials
- Amgen Inc.2 trials
- Boehringer Ingelheim2 trials
- and 19 more
Running trials
Recruiting
Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial (ARIEL)
2025-521985-82-00· Phase 2· Woerwag Pharma GmbH & Co. KG· Source
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Recruiting
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Recruiting
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· Phase 2· Abivax S.A.· Source
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· Phase 2· AstraZeneca· Source
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Abivax S.A.· Source
Active, not recruiting
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· Phase 3· Pfizer· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068· Phase 3· AbbVie· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Withdrawn
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07313774· Phase 3· Cinclus Pharma Holding AB· Source
Completed
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
NCT07037875· Phase 3· Cinclus Pharma Holding AB· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· CSL Behring· Source
Completed
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.
NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Active, not recruiting
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934· Phase 2· Gilead Sciences· Source
Completed
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05672199· Phase 2· Amgen Inc.· Source
Active, not recruiting
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843· Phase 2· Sanofi· Source
Completed
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203· Phase 3· Abivax S.A.· Source
Completed
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis
NCT04987307· Phase 2· Amgen Inc.· Source
Completed
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
2023-509233-39-00· Phase 2· Oppilan Pharma Limited· Source
Completed
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT04996797· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source
Completed
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
2024-513569-38-00· Phase 2/3· Arena Pharmaceuticals Inc.· Source
Completed
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
NCT04029480· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· Phase 3· Celgene International II SARL· Source
Report an error